[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Australasian Gastro-Intestinal Trials Group\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":111},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,40,63,84],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100562543","magnetic-resonance-imaging-mri-guided-stereotactic-adaptive-radiotherapy-for-targeting-abdominal-cancer-100562543",false,"NCT06604533","Magnetic Resonance Imaging (MRI) Guided Stereotactic Adaptive Radiotherapy for Targeting Abdominal Cancer","A Randomized Phase II Trial - Magnetic Resonance Imaging (MRI) Guided Stereotactic Adaptive Radiotherapy for Targeting Abdominal Cancer","Inclusion Criteria:\n\n* Aged 18 years or older\n* Patients with diagnosis of oligometastatic disease from primary colorectal, upper gastrointestinal (e.g. gastric, oesophagus, pancreatic), breast, non-small cell lung, renal cell, or gynaecological malignancy. Oligometastatic disease with controlled primary disease\\* and maximum total of 5 metastatic lesions in a maximum of 2 different organ systems in any of the following sites:\n\n  1. Liver\n  2. Adrenal\n  3. Abdomino-pelvic lymph node\n  4. Other abdominal site e.g. pancreatic, renal.\n  5. Other pelvic site\n  6. Bony or lung is allowed only if in conjunction with an abdominal site above\n* De novo or metachronous oligometastatic disease where the original tumour site has been treated with curative intent.\n\n  * Controlled primary disease in metachronous oligometastastic disease defined as at least 3 months since original tumour treated with curative intent and no progression at primary site\n  * Controlled primary disease in de novo oligometastatic disease defined as primary tumour site treated with curative intent and no progression at primary site\n* Oligometastatic disease: Histological confirmation of primary malignancy (histological confirmation of metastasis is not mandatory but should be performed in any situation where there is any diagnostic uncertainty).\n* All oligometastatic sites treatable with SABR.\n\nOR\n\n* Patients with oligo-progressive \u002F oligo-persistent disease in maximum total of 2 oligo-progressive abdominal metastases and in a maximum 2 different organ systems\n* Visible imaging defined targets and suitable for treatment with SABR\n* Childs Pugh A to B7 (in case of liver treatment)\n* ECOG 0 -2\n* Patient consented\n\nExclusion Criteria:\n\n* Contra-indication to MRI\n* Previous high dose radiotherapy to a site requiring stereotactic treatment (including SIRTEX). Further SABR treatment of lesions previously treated with SABR or high dose radiotherapy is not permitted in this trial.\n* Substantial overlap with a previously treated high dose (definitive or stereotactic dose) radiation volume.\n* Primary prostate cancer, carcinoid tumours, germ cell tumours, lymphoma, small cell tumours\n* Pregnant women\n* Complete response of metastatic disease to systemic therapy (i.e. no target for SABR)\n* Competing medical co-morbidity with a more limited prognosis than the cancer diagnosis","ALL","18 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"NA","The aim of this study is to investigate the effect of MRI-guided adaptive stereotactic radiotherapy on local control, survival, and toxicity in the treatment of oligometastatic cancer to the abdomen.",[26],"Abdominal Cancer","RECRUITING","2026-05-05",{"date":30,"type":31},"2026-05-08","ACTUAL",{"date":33,"type":31},"2025-07-07",{"date":35,"type":20},"2030-01",{"name":37,"class":38},"Australasian Gastro-Intestinal Trials Group","NETWORK",2,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":21,"phases":48,"briefSummary":50,"conditions":51,"keywords":53,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":62},"100550029","phase-2-phase-ii-study-of-the-combination-of-durvalumab-medi4736-pdl1-inhibitor-and-olaparib-parp-inhibitor-in-advanced-cholangiocarcinoma-after-initial-chemotherapy-and-durvalumab-bil-ppp-100550029","NCT06441747","Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)","Inclusion Criteria:\n\n1. Age ≥18 years, and life expectancy\\>12 weeks\n2. Weight: \\>30kg\n3. Histologically proven locally advanced or metastatic\u002Funresectable cholangiocarcinoma\n4. Documentation of RECISTv1.1 measurable disease\n5. Must not have had radiologic progression after 6-8 cycles of gemcitabine and cisplatin and durvalumab\n6. Adequate haematological and end-organ function as defined by the following parameters:\n\n   1. Haemoglobin ≥ 90g\u002FL (without a transfusion in the past two weeks)\n   2. Platelets ≥100 x 109\u002FL (without a transfusion in the past two weeks)\n   3. Neutrophils ≥ 1.0 x 109\u002FL (without the use of G-CSF in the 4 weeks prior to first dose)\n   4. ALT\u002FAST \\\u003C3x ULN irrespective of presence of liver metastases\n   5. Serum bilirubin ≤ 1.5x ULN except in cases of known Gilbert's Syndrome where total bilirubin must be \\\u003C4x ULN\n   6. Albumin ≥ 25 g\u002FL\n   7. Serum Creatinine ≤1.5 x ULN or eGFR ≥ 30mL\u002Fmin\u002F1.73m2 as calculated by Cockcroft Gault Equation\n7. Able to swallow oral medications without any difficulties or medical history associated with malabsorption or any conditions that may impact on compliance or absorption of the study treatment.\n8. Women of Childbearing potential must be either totally abstinent or agree to use at least one highly effective method of birth control (e.g., oral contraceptive pill, barrier method) for the duration of the study and for at least 6 months after the final dose of study medication. They must also have a negative serum beta-hCG in the 7 days prior to first dose of study drug.\n9. Non-sterile males and their female partners must also either be totally abstinent or agree to use at least one highly effective method of birth control (e.g., oral contraceptive pill, barrier method) for the duration of the study and for at least 6 months after the final dose of study medication.\n10. Patient is willing and able to comply with the protocol for the duration of the study, including undergoing treatment and scheduled visits and examinations including follow up.\n11. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. Written informed consent and any locally required authorization obtained from the patient\u002Flegal representative prior to performing any protocol-related procedures, including screening evaluations.\n\nExclusion Criteria:\n\n1. Previous use of a PARP inhibitor.\n2. All prior treatment-related AEs must have resolved to a CTCAE v5 Grade 1 or less prior to commencement of study medication, with the exception of alopecia and peripheral neuropathy which can be grade 2 or less.\n\n   i. Patients with Grade ≥2 neuropathy will be evaluated on a case-by-case basis after consultation with the Study Physician.\n\n   ii. Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab or olaparib may be included only after consultation with the Study Chairs.\n3. Known symptomatic or progressive CNS metastases or leptomeningeal disease. Patients with treated brain metastases are eligible for inclusion in the study if they had received treatment \\>4 weeks prior to commencement of study medication, and have a repeat MRI scan demonstrating stability in disease.\n4. Patients with severe chronic or active infections requiring systemic antibiotics or antifungals in the two weeks prior to starting trial treatment.\n5. Any of the following cardiovascular risk factors:\n\n   1. Acute myocardial infarction (MI) ≤6 months prior to study registration\n   2. New York Heart Association (NYHA) Heart Failure Class III-IV within ≤6 months of registration\n   3. History of cerebral vascular accident (CVA) within 6 months of first dose\n6. Concurrent enrolment in another clinical study, unless it is an observational (non-interventional) clinical study, or during the follow-up period of an interventional study.\n7. Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks of the first dose of study drug.\n8. Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of IP. Note: Local surgery of isolated lesions for palliative intent is acceptable.\n9. History of allogeneic organ transplantation.\n10. Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease \\[e.g., colitis or Crohn's disease\\], diverticulitis \\[with the exception of diverticulosis\\], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome \\[granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc\\]). The following are exceptions to this criterion:\n\n    1. Patients with vitiligo or alopecia.\n    2. Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement.\n    3. Any chronic skin condition that does not require systemic therapy.\n    4. Patients without active disease in the last 5 years may be included but only after consultation with the study physician.\n    5. Patients with celiac disease controlled by diet alone.\n11. Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhoea, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements, substantially increase risk of incurring AEs, or compromise the ability of the patient to give written informed consent.\n12. History of another primary malignancy except for:\n\n    1. Malignancy treated with curative intent and with no known active disease ≥2 years before the first dose of IP and of low potential risk for recurrence.\n    2. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.\n    3. Adequately treated carcinoma in situ without evidence of disease.\n13. Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥470 ms calculated from 3 ECGs (within 15 minutes at 5 minutes apart).\n14. History of active primary immunodeficiency.\n15. Known active hepatitis infection, positive hepatitis C virus (HCV) antibody, hepatitis B virus (HBV) surface antigen (HBsAg) or HBV core antibody (anti-HBc), at screening. Participants with a past or resolved HBV infection (defined as the presence of anti HBc and absence of HBsAg) are eligible. Participants positive for HCV antibody are eligible only if polymerase chain reaction is negative for HCV RNA.\n\n    1. Participants co-infected with HBV and HCV, or co-infected with HBV and HDV, namely: HBV positive (presence of HBsAg and\u002For anti HBcAb with detectable HBV DNA); AND\n    2. HCV positive (presence of anti-HCV antibodies); OR\n    3. HDV positive (presence of anti-HDV antibodies).\n16. Known to have tested positive for human immunodeficiency virus (HIV) (positive HIV 1\u002F2 antibodies) or active tuberculosis infection (clinical evaluation that may include clinical history, physical examination and radiographic findings, or tuberculosis testing in line with local practice). Known HIV infection that is not well controlled. All of the following criteria are required to define an HIV infection that is well controlled: undetectable viral RNA load for 6 months prior, CD4+ count of \\>500, no history of AIDS-defining opportunistic infection within the past 12 months, and stable for at least 6 months on the same anti-HIV medications.\n17. Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab. The following are exceptions to this criterion:\n\n    1. Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra-articular injection)\n    2. Systemic corticosteroids at physiologic doses that do not exceed 10 mg\u002Fday of prednisolone or its equivalent.\n    3. Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)\n18. Receipt of live attenuated vaccine within 30 days prior to the first dose of IP. Note: Patients, if enrolled, should not receive live vaccine whilst receiving IP and up to 90days after the last dose of IP.19. Female patients who are pregnant or breastfeeding, or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of durvalumab monotherapy.\n\n20\\. Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.\n\n21\\. Judgment by the investigator that the patient is unsuitable to participate in the study and the patient is unlikely to comply with study procedures, restrictions and requirements.",{"count":47,"type":20},40,[49],"PHASE2","The aim of this study is to investigate whether the combination of durvalumab and olaparib in the maintenance setting after initial chemotherapy and durvalumab will benefit patients with locally advanced or metastatic cholangiocarcinoma.",[52],"Cholangiocarcinoma",[54],"Advanced Cholangiocarcinoma",{"date":56,"type":31},"2026-05-06",{"date":58,"type":31},"2024-09-23",{"date":60,"type":20},"2028-08",{"name":37,"class":38},8,{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":71,"targetDuration":4,"studyType":21,"phases":73,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":77,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},"100538413","phase-2-a-trial-of-palliative-chemotherapy-radiation-and-immune-treatment-for-oesophageal-cancer-paleo-study-100538413","NCT06290505","A Trial of Palliative Chemotherapy, Radiation and Immune Treatment for Oesophageal Cancer: PALEO Study","PALEO: Phase II Clinical Trial of Chemoradioimmunotherapy for the ALleviation of oEsOphageal Cancer Complications","PALEO","Inclusion Criteria:\n\n1. Males and females \\> 18 years of age.\n2. Biopsy proven adenocarcinoma or squamous cell carcinoma of the esophagus or gastro-oesophageal junction\n3. Oligometastatic disease (1-5 lesions outside the primary tumour radiotherapy field on FDG-PET scan), or locoregionally advanced disease unsuitable for either surgical resection or radical chemoradiotherapy\n4. Symptomatic dysphagia (Mellow score greater than 0)\n5. ECOG performance status 0-2\n6. Anticipated life expectancy of greater than 12 weeks.\n7. Body weight of greater than 30kg.\n8. Adequate bone marrow function, with values within the ranges specified below. Blood transfusions are permissible.\n\n   1. White blood cell count greater than or equal to 2 x (10 to the power of 9)\u002FL\n   2. Absolute neutrophil count greater than or equal to 1.5 x (10 to the power of 9)\u002FL\n   3. Platelets greater than or equal to 100 x (10 to the power of 9)\u002FL\n   4. Haemoglobin greater than or equal to 90g\u002FL\n9. Adequate liver function, with values within the ranges specified below:\n\n   1. Alanine transferase less than or equal to 2.5 x upper limit of normal (ULN)\n   2. Aspartate transferase less than or equal to 2.5 x ULN\n   3. Total bilirubin less than or equal to 1.5 x ULN (except patients with Gilbert's Syndrome, who can have total bilirubin less than or equal to 5 x ULN)\n10. Adequate renal function, with values within the ranges specified below. Note that an estimated renal function of greater than 125mL\u002Fmin by the Cockroft-Gault formula must not be used for carboplatin dosing, and must instead be determined using a direct method.\n\n    1. Serum creatinine less than or equal to 1.5 x ULN\n    2. Creatinine clearance (CrCl) greater than or equal to 40 mL\u002Fmin using Cockroft-Gault formula\n11. Tumour tissue (formalin-fixed, paraffin embedded) should be available for PD-L1 and mismatch repair (MMR) protein expression and can be provided as a block or slides (archival tissue is acceptable). Blocks prepared from cytological samples, where tumour cell number is sufficient, are also acceptable. Patients will not be selected by PD-L1 or MMR status.\n12. Willing and able to comply with all study requirements, including treatment, timing and\u002For nature of required assessments.\n13. Signed, written and informed consent.\n\nExclusion Criteria:\n\n1. Bulky or organ-threatening metastatic disease requiring upfront higher dose chemotherapy in the judgement of the treating clinician.\n2. Known tumour HER2 positivity (IHC 2+ or more and HER2 gene amplification on in situ hybridisation) if oligometastatic disease.\n3. Previous systemic therapy for oesophageal or GOJ carcinoma.\n4. Previous thoracic radiotherapy. Prior palliative radiotherapy to bony metastases is permitted.\n5. Esophageal stent in situ.\n6. Known tracheo-oesophageal fistula.\n7. Known leptomeningeal or brain metastases.\n8. Major surgical procedure (as defined by the Investigator) within 28 days prior to first day of study treatment. Note: Local surgery of isolated lesions for palliative intent is permitted.\n9. History of another malignancy within the last 3 years, with the exception of adequately treated non-melanomatous skin cancer, carcinoma in situ and superficial transitional cell carcinoma of the bladder.\n10. Prior therapy with an anti-PD1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T cell co-stimulation or immune checkpoint pathways.\n11. Sensory neuropathy of grade 2 or higher severity per CTCAE v5.0.\n12. History of allergy or hypersensitivity to study drug components, or other contraindications to any of the study drugs. Active or prior documented autoimmune disorders (including inflammatory bowel disease \\[e.g., ulcerative colitis or Crohn's disease\\], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome \\[granulomatosis with polyangiitis\\], Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc). Patients with the following conditions are exceptions to this criterion:\n\n    1. Vitiligo or alopecia.\n    2. Hypothyroidism (e.g., following Hashimoto syndrome) stable on thyroid hormone replacement.\n    3. Any chronic skin condition (e.g. psoriasis) that does not require systemic therapy.\n    4. Type 1 diabetes mellitus.\n    5. Coeliac disease controlled by diet alone.\n\n    Patients without active autoimmune disease in the last 5 years may also be included but only after consultation with the Chief Principal Investigators.\n13. Any condition requiring continuous systemic treatment with either regular corticosteroids (\\>10mg daily prednisone or equivalent dose of an alternative corticosteroid) or other immunosuppressive medications within 14 days of study drug administration. Intranasal, inhaled or topical steroids, and adrenal replacement steroid doses \\>10mg daily oral prednisone equivalent, are permitted in the absence of active autoimmune disease.\n14. Positive test for hepatitis B surface antigen (HBsAg) indicating acute or chronic infection. Participants with a past or resolved HBV infection (defined as the presence of anti-HBc and absence of HBsAg) are eligible.\n15. Positive test for hepatitis C virus antibody (HCV antibody) , unless polymerase chain reaction is negative for HCV RNA.\n16. History of other significant, or active, infection, including HIV or tuberculosis (TB). HIV testing is not mandatory unless clinically indicated. Clinical evaluation for active TB may include clinical history, physical examination and radiographic findings, or tuberculosis testing in line with local practice.\n17. Receipt of a transplanted solid organ (kidney, liver, heart or lung) or of an allogeneic bone marrow transplant.\n18. Receipt of a live attenuated vaccine within 30 days prior to registration.\n19. Use of alternative or traditional medicines within 14 days prior to registration.\n20. Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirement, substantially increase risk of incurring adverse events or compromise the ability of the patient to give written informed consent.\n21. Pregnancy, lactation, or inadequate contraception. Women must be post-menopausal, infertile, or use a reliable means of contraception to avoid pregnancy for 90 days after the last dose of durvalumab. Women of childbearing potential must have a negative pregnancy test within 24 hours prior to trial registration. Men must have been surgically sterilized or use a double barrier method of contraception if they are sexually active with a woman of childbearing potential for a period of 180 days after the last dose of durvalumab and chemotherapy, or 90 days after the last dose of durvalumab monotherapy (whichever is the longer time period). Sperm donation is not permitted for 180 days after the last dose of durvalumab and chemotherapy, or 90 days after the last dose of durvalumab monotherapy (whichever is the longer time period).",{"count":72,"type":20},54,[49],"The purpose of this study is to investigate the effects of the addition of the stereotactic body radiotherapy and durvalumab to a well tolerated 2 week chemotherapy and radiation treatment regimen in people with esophageal cancer that is locally advanced or has spread to another area of the body (metastasized).",[76],"Esophageal Cancer",{"date":30,"type":31},{"date":79,"type":31},"2021-12-08",{"date":81,"type":20},"2029-07-31",{"name":37,"class":38},9,{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":21,"phases":94,"briefSummary":95,"conditions":96,"keywords":98,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},"100542608","phase-2-cessation-of-somatostatin-analogues-after-prrt-in-mid-hind-gut-and-pancreatic-neuroendocrine-tumours-100542608","NCT06345079","Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours","A Randomised Study of Cessation of Somatostatin Analogues After Peptide Receptor Radionuclide Therapy in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours (STOPNET)","STOPNET","Inclusion Criteria:\n\n* Adults over 18 years of age with well or moderately differentiated mid or hindgut neuroendocrine tumour, or pancreatic neuroendocrine tumour, metastatic and inoperable, demonstrating progression despite SSA treatment of sufficient disease magnitude to warrant PRRT as determined by the treating clinician and\u002For the NET Multidisciplinary Team (MDT).\n* Must have measurable disease on triphasic CT\u002FMRI as per RECIST 1.1.\n* Ki67 ≤ 20% AND mitotic count 20 per HPF (i.e., WHO grade 1 or 2)\n* Patient has been receiving growth-controlling doses of SSA for at least 12 weeks prior to study entry. This is a minimum of 30 mg Octreotide or120mg lanreotide monthly.\n* Uptake on SSTR PET scan demonstrating somatostatin receptor expression that is suitable for PRRT as judged by the clinical team. FDG PET scans are to be done at the judgement of the treating team and are not required for enrolment into this study.\n* PRRT is deemed the most appropriate next treatment step (i.e., patient is inoperable, and liver directed therapies are not preferred)\n* ECOG performance status 0 -2\n* Written informed consent. Patients must be willing to either cease or continue SSA, depending on which study arm they are randomised to. Patients must be willing to comply with all other study requirements\n* Adequate renal, hepatic and haematologic function as judged by the treating team\n* Life expectancy of at least 12 months\n* Availability of tissue from resection or biopsy samples is desired but is not mandatory for study inclusion. Tissues will only be retrieved if the patient consents to optional translational research sample collection. Similarly, bloods for research purposes will only be collected from those patients who consent to optional translational research sample collection.\n* Non-functioning NET: SSA treatment will have been commenced for control of tumour growth and not for carcinoid or other hormone overproduction syndrome, as judged by the clinician and\u002For NET MDT. Non-functioning NET is judged by the treating clinical team based on patient symptomatology. In addition, for this study, non-functioning tumour is defined as:\n\n  * 24-hour urine 5-hydroxyindoleacetic acid (5HIAA) of \\\u003C1.5x upper limit of normal (applies to mid and hind gut patients only).\n  * Please note: routine measurement of gastrin, insulin, C-peptide levels, glucagon etc. is not required unless clinically indicated.\n  * Never had escalation of the SSA treatment dose to control carcinoid carcinoid or other hormone-related symptoms\n  * Never required short acting SSA treatment to control carcinoid carcinoid or other hormone-related symptoms\n  * No significant carcinoid induced valvular heart disease IE: Echocardiogram to be done in all patients within 26 weeks of study enrolment and deemed safe to proceed with PRRT by the treating team.\n\nExclusion Criteria:\n\n* This study is for pancreatic, mid-gut and hind-gut NET only. Gastric and lung NETs are excluded\n* Any patient on an SSA dose lower than the standard growth-control dose. Patients must have been on octreotide 30 mg or lanreotide 120 mg for at least 3 months prior to study entry.\n* Prior chemotherapy or targeted therapy (e.g., everolimus). Patients who have received prior local therapy, including external beam radiotherapy and liver directed therapy prior to or during SSA therapy are eligible.\n* Any contraindication to PRRT, as per local institutional practice.\n* Pregnancy. For female patients of childbearing potential and male patients with a female partner who is of childbearing potential, contraception and counselling is required.\n* Prior PRRT. Patients being considered for re-treatment with PRRT are not eligible\n* Uncontrolled central nervous system metastases. Patients must have completed any surgery or radiation at least 4 weeks prior to registration and must be off corticosteroids for at least 2 weeks\n* Any patient, in the opinion of the investigator, who will not comply with study assessments and follow up visits. These might include any social, psychological, or geographical concerns, including alcohol\u002Fdrug abuse\n* Any poorly controlled concurrent medical illness that may prevent the patient from complying with study assessments and follow up. This is to be judged by the treating team\n* Any concurrent or prior malignancy that, in the opinion of the treating team, may interfere with study assessments and endpoints",{"count":93,"type":20},78,[49],"Neuroendocrine tumours (NETs) are slow growing cancers, which commonly present as metastatic incurable disease. Some neuroendocrine tumours, termed functional NETs, overproduce hormones which result in a variety of symptoms. However, approximately 75% of NETs are considered non-functional meaning that they do not result in hormone overproduction. The main treatment for both functional and non-functional NETs is somatostatin analogues (SSA, a type of inhibitory hormone). These drugs slow tumour growth and reduce hormone production. Over time, the majority of patients will experience tumour growth despite treatment with SSA therapy. When this occurs, the addition of Peptide Receptor Radionuclide Therapy (PRRT, a type of targeted radiotherapy) in combination with ongoing SSA therapy is given. However, it is not known if continuing SSA therapy after commencement of PRRT is beneficial or not.\n\nThe aim of this study is to estimate the outcomes of patients with grade 1 and 2 well differentiated mid, hind-gut or pancreatic neuroendocrine tumours who have progressed on SSA therapy and receive subsequent PRRT with or without concurrent SSA.",[97],"Neuroendocrine Tumors",[99,100,101],"Advanced","Unresectable grade 1 or 2","mid, hind- gut or pancreatic neuroendocrine tumours","2025-08-11",{"date":104,"type":31},"2025-08-14",{"date":106,"type":31},"2024-10-14",{"date":108,"type":20},"2028-06",{"name":37,"class":38},12,""]